Frank Ruffo compensation by year
Aclaris Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Salary | $390,000 | $390,000 | $401,700 | $417,768 |
| Bonus | $0 | $0 | $0 | — |
| Stock awards | $651,990 | $125,453 | $798,792 | $705,644 |
| Option awards | $0 | $105,356 | $1,873,125 | $1,871,960 |
| Non-equity incentive | $109,200 | $179,400 | $177,551 | $167,107 |
| Pension and deferred compensation | $0 | $0 | $0 | — |
| All other | $11,688 | $11,868 | $11,600 | $12,200 |
| Total | $1,162,878 | $812,077 | $3,262,768 | $3,174,679 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 20, 2023, accession 0001558370-23-006263, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-23-006263. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 44,300 | $697,725 | — |
| RSU | 25,750 | $405,563 | — |
| RSU | 24,900 | $392,175 | — |
| RSU | 16,595 | $261,371 | — |
| Option | 155,200 | — | $14.94 |
| Option | 58,080 | — | $1.26 |
| Option | 87,000 | — | $24.06 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Aclaris Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Neal Walker | Chief Executive Officer | $5,836,727 |
| Gail Cawkwell | Chief Medical Officer | $3,299,008 |
| Douglas Manion | President and Chief Operating Officer | $3,202,198 |
| Frank Ruffo · this page | Chief Financial Officer | $3,174,679 |
| Joseph Monahan | Chief Scientific Officer | $2,822,982 |
The full Aclaris Therapeutics compensation record
free company briefThis page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Aclaris Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.